Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks Randy. I was thinking from the angle of if there will be less likelihood of a CRL because of the reduced review period.
NBRV--PDUFA for CONTEPO was moved from June 30 to April 30. Anyone following this ticker by any chance? Also does a shortened review period mean much in your opinion? TIA.
http://investors.nabriva.com/news-releases/news-release-details/nabriva-therapeutics-provides-update-pdufa-date-intravenous
CDTX—9 presentations at ECCMID 2019. Details in thread below:
$CDTX Abstracts for ECCMID 2019...huge weekend with 9 presentations April 13-16
— BioDonor™ (@BioDonor) April 12, 2019
Thank you Bladerunner. It seems they had $75M as of 12/31. Do they have a high burn rate? I will have to look into it. They will probably raise after this weekend’s data.
Thanks for your response Bladerunner. I do have a small position in CDTX. Given the heightened attention to super fungi lately, it might be worth a shot to have a speculative position in either one. Cheers.
SCYX CDTX: Any thoughts on this tweet bladerunner1717?
https://twitter.com/fezziwig2008/status/1116017318440648704?s=20
It appears that way. Thanks Dew (eom).
CFRX +23% on below PR:
ContraFect Announces Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
https://www.globenewswire.com/news-release/2019/04/04/1796930/0/en/ContraFect-Announces-Presentations-at-the-29th-European-Congress-of-Clinical-Microbiology-and-Infectious-Diseases-ECCMID.html
Four presentations at this conference. Any thoughts on this company since the disappointing p2 data in January? Could they still salvage their pipeline? Thanks.
For some odd reason (I am glad they did) they updated clinicaltrials. gov primary completion date from Feb 2019 to Feb 2021 two days ago. Was not comfortable with that when I found out yesterday so luckily I closed my small position before EOD yesterday.
I am not in AMRN but saw the update. It is really impressive. BO or no BO this stock will double eventually IMO. Congrats if you are in it! Fingers crossed for a BO soon.
Thank you for your response Whalatane. Makes more sense to me now and I agree it could actually be a bullish indicator. Why extend a failed trial? And if they were redoing it, they would probably need to open a new trial profile on clinical trials. gov after having discussions with the FDA, and not just update a failed trial profile.
Having said that, I also agree on this being a high R/R investment and investing only what one can afford to lose will be important. Cheers.
That’s what I thought as well. Wasn’t sure if it was common to extend this date field for follow up studies.
Just noticed estimated primary completion date has been updated from Feb 2019 to Feb 2021. Not sure what this means but isn’t confidence building.
Looks like clinicaltrials was updated yesterday too. I don’t want to connect the two events but it’s fun to think about.
https://clinicaltrials.gov/ct2/show/NCT02414841
Special Report on Immunology & Autoimmunity: Turn of the coin
http://ddn-news.com/index.php?pg=77&articleid=13140
I’ve been thinking, to share data this month they would have most likely unblinded trial in February. They PR’d they are attending Cowen Healthcare Conference on March 4. It would be pointless attending this conference if they have failed the trial.
Unless they still haven’t unblinded the results...
SA article from Bret Jensen:
Genome editing company Precision proposes $100M IPO
https://www.biocentury.com/bc-extra/financial-news/2019-03-01/genome-editing-company-precision-proposes-100m-ipo
NVAX -69% /PM after trial of ResVax misses its main goal
https://www.marketwatch.com/story/novavax-shares-crater-69-premarket-after-trial-of-resvax-misses-its-main-goal-2019-02-28
Fully diluted they have roughly 50M shares (warrants, employee stock options). Need a ~$100M BO for $2. Their estimated market will be $500M so a $100M BO not impractical IMO. Personally I’d be happy with $50M-$75M. Having said that if they can produce good sales numbers this year, they can aim for a better valuation than $100M.
Agreed (eom)
*NVS
AMRN +12% on NVO buyout rumor
https://www.streetinsider.com/dr/news.php?id=15168230
SLDB (-73%/PM) to soldier on as initial muscular dystrophy gene therapy results disappoint
https://www.statnews.com/2019/02/07/solid-biosciences-muscular-dystrophy-gene-therapy-disappoint/
AGN tries to blunt impact of Botox competitor with complaint of pilfered manufacturing secrets
https://www.fiercepharma.com/manufacturing/allergan-tries-to-blunt-impact-botox-competitor-complaint-pilfered-manufacturing
MBOT +307% — Recent Study Validates the Operational Effectiveness of Microbot Medical’s Self-Cleaning Shunt (SCS™)
https://finance.yahoo.com/news/recent-study-validates-operational-effectiveness-120100006.html
Oil majors bet on turning air into jet fuel
Oil majors bet on turning air into jet fuel https://t.co/NBbcy8lHV4
— Financial Times (@FT) January 9, 2019
SESN -36% on preliminary Vicinium NMIBC 12 month-data
https://www.businesswire.com/news/home/20190103005202/en/Sesen-Bio-Announces-Positive-Preliminary-12-Month-Data
U.S. Becomes a Net Oil Exporter for First Time in 75 Years
http://fortune.com/2018/12/06/oil-exports-us/
[OT]Bacteria found in ancient Irish soil halts growth of superbugs—new hope for tackling antibiotic resistance
https://phys.org/news/2018-12-bacteria-ancient-irish-soil-halts.html#jCp
[OT]300 Blind Mice Uncover Genetic Causes of Eye Disease
https://www.ucdavis.edu/news/300-blind-mice-uncover-genetic-causes-eye-disease/
AVGR—Doctors in Australia have used a new device in their fight against clogged arteries
https://twitter.com/avingerinc/status/1074792855053438976?s=21
AVGR got into legal trouble with their previous device. The stock used to trade much higher couple of years ago. The lawsuit was settled this year. Remains to be seen if they can do things properly this time. 510K decision should be due by February (submitted end of August). I hold a small position.
Harvard Quietly Amasses California Vineyards—and the Water Underneath
https://www.wsj.com/articles/harvard-quietly-amasses-california-vineyardsand-the-water-underneath-1544456396
[OT]How drug companies make you buy more medicine than you need
1/ In its current state, $BTC is easier to dismiss than understand. In this extensive report, we discuss the long-term potential of the world’s most valuable cryptocurrency and the key obstacles it must overcome on its path towards wider acceptance and adoption. pic.twitter.com/YC21dVNwtI
— Delphi Digital (@Delphi_Digital) December 10, 2018
Bullion Giant APMEX Partners with BitPay to Let Investors Buy Gold with Bitcoin
https://www.ccn.com/bullion-giant-apmex-partners-with-bitpay-to-let-investors-buy-gold-with-bitcoin/
https://www.apmex.com/now-accepting-bitcoin?force-full-site=1
The most influential endowment manager just jumped into crypto with bets on two Silicon Valley funds
https://www.cnbc.com/amp/2018/10/05/yale-investment-chief-david-swensen-jumps-into-crypto-with-bets-on-two-silicon-valley-funds.html
Gold remains the only asset on the planet for which China can buy 50-75% of global mine output for 6 straight years and have the price do...nothing.
— Luke Gromen (@LukeGromen) December 7, 2018
Cash-settled futures on a monetary asset doing their job (dampening prices) = None of this will matter until it matters. https://t.co/iqdAIEGJE8
A cancer drug that AbbVie acquired in a $10 billion deal is looking more and more like a failure
https://www.businessinsider.com/abbvie-stopped-a-phase-3-trial-after-its-stemcentrx-drug-flopped-2018-12
J&J shells out $500M to sew up Argenyx's blood cancer hopeful cusatuzumab
https://www.fiercebiotech.com/biotech/ash18-argenx-pens-1-6b-biobucks-janssen-pact-for-blood-cancer-hopeful